Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 1,694 trials

Splenic Marginal Zone Lymphoma: Rituximab with Zanubrutinib

We are comparing the effects of adding zanubrutinib to rituximab versus using rituximab alone in patients with untreated splenic marginal zone lymphoma. The goal is to see if the combination improves survival and response rates.

Splenic Marginal Zone Lymphoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

Post-Menopausal Osteoporosis: BP16 vs. EU-Prolia

We are comparing a new treatment, BP16, to EU-Prolia for women with post-menopausal osteoporosis. The study looks at how well each treatment improves bone health and their safety.

Post-Menopausal Osteoporosis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Gastroparesis: Tradipitant Safety Study

We are evaluating the safety of a new medication, tradipitant, for patients with gastroparesis. The study also looks at how well it may help reduce symptoms and improve quality of life.

Gastroparesis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Major Depressive Disorder: Lumateperone Study

We are testing lumateperone as an additional treatment for people with major depressive disorder who aren't responding well to their current antidepressants. The study will help us understand its effectiveness and safety.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Lung Cancer: Zipalertinib Study

We are testing Zipalertinib in patients with advanced non-small cell lung cancer who have specific genetic mutations. The goal is to see if it is safe and effective in treating their condition.

Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Endometrial Cancer: Olaparib Maintenance Therapy

We are studying whether olaparib can help prevent cancer recurrence in patients with p53abn endometrial cancer after they receive chemoradiation. This trial compares olaparib treatment to observation alone.

p53abn HREC Patients Post-Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsOncology

Sildenafil for Adults with Univentricular Heart Post-Fontan

We are studying whether adding sildenafil to existing treatments can improve physical performance and quality of life in adults with a univentricular heart after Fontan surgery.

Fontan Procedure and Univentricular Heart3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyHematologyInternal MedicinePediatrics

Locally Advanced NSCLC: Alectinib vs. Durvalumab

We are studying whether alectinib or entrectinib is more effective than durvalumab for patients with advanced non-small cell lung cancer who have not progressed after initial treatment. The trial also looks at quality of life and safety for participants.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Geographic Atrophy: Tinlarebant Treatment Study

We are exploring whether Tinlarebant can slow the growth of lesions in people with geographic atrophy and improve their vision. This study compares the new treatment to a placebo to assess its effectiveness.

Geographic Atrophy>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Ectopic Pregnancy: Mifepristone and Letrozole vs. Methotrexate

We are studying whether a new combination treatment is as effective as the standard medication for ectopic pregnancy. This trial will also look at side effects and the need for further medical interventions.

Ectopic Pregnancy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and Obstetrics

Progressive Glioblastoma: Perampanel Treatment Study

We are studying whether the medication Perampanel can help reduce tumor growth in patients with progressive glioblastoma before surgery. This trial also looks at quality of life and cognitive function to see how the treatment affects patients.

Progressive Glioblastoma>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyOncology

Graft-versus-Host Disease: MC0518 Treatment for Kids

We are studying a new treatment called MC0518 for children with steroid-refractory acute graft-versus-host disease after stem cell transplant. The goal is to see if it works better than the best available therapy.

Steroid Refractory Acute Graft Versus Host Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

Nitroglycerin for Esophageal Food Impaction

We are studying whether nitroglycerin can help relieve food impaction in the esophagus. This trial aims to see if it is an effective treatment for those who have trouble swallowing.

Esophageal Food Impaction>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyOtolaryngology

Growth Hormone Deficiency: LUM-201 Treatment Study

We are monitoring the long-term safety of LUM-201 in children with idiopathic growth hormone deficiency. This study also looks at how the treatment affects growth and related health markers.

Idiopathic Growth Hormone Deficiency>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics

Dapagliflozin for Heart Health in Amyloid Transthyretin Cardiac Amyloidosis

We are studying how dapagliflozin may improve exercise capacity and quality of life for patients with ATTR-CA. This trial will also look at its safety and other health markers.

Cardiac Amyloidosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Tailored Ibrutinib Treatment

We are studying how personalized dosing of ibrutinib can improve treatment for patients with previously untreated chronic lymphocytic leukemia. The goal is to see if adjusting the dose based on side effects leads to better outcomes.

Chronic Lymphocytic Leukemia (CLL)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

LiBRA: Lithium for Cognitive Protection After Brain Radiotherapy

We are studying whether lithium can help prevent cognitive problems in children who received brain radiotherapy for cancer. The trial also looks at overall quality of life and safety of the treatment.

Brain Tumor3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyOncology

Personalized Anti-Platelet Therapy for Coronary Artery Disease

We are studying whether a genetic test-guided treatment improves blood platelet function in patients with stable coronary artery disease undergoing stenting. This may help determine the best anti-platelet therapy for individual patients.

Stable Coronary Artery DiseaseChronic Coronary Syndrome3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Primary Biliary Cholangitis: Bezafibrate Treatments

We are studying the effects of two doses of bezafibrate in patients with primary biliary cholangitis who aren't responding well to current therapy. The goal is to see if these treatments can improve symptoms and liver health.

Primary Biliary Cholangitis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesGastroenterologyHepatology